Tag:

Gilenya

Latest Headlines

Latest Headlines

Novartis, Biogen Idec release more strong data on hot-selling MS pills

The day after showing that two of their respective therapies provided better results with earlier treatments, the companies followed up with analyses of safety and brain volume loss for their oral drugs, both of which have already gained significant market share in treating the disease.

Top 15 Drug Launch Superstars

Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>

Novartis' MS drug Gilenya tied to rare brain infection

Novartis' Gilenya, which a consumer watchdog group last year pegged with safety concerns, is again being called into question after a patient taking the MS drug developed a rare brain infection.

Novartis MS drug prevents heart failure in animal study

Scientists believe a drug approved to treat multiple sclerosis may also be able to help prevent an unrelated medical condition--heart failure.

Novartis under U.S. scrutiny for Gilenya marketing tactics

Novartis is up against another marketing investigation. A U.S. Attorney's Office in New York has demanded documents and information about its Gilenya promotions, adding to a list of other government probes.

European regulators tag 100-plus drugs with 'black triangle'

The labeling logo is designed to encourage doctors and patients to report side effects, as part of a new effort to more closely monitor drug safety. The list of 100-plus products includes all new drugs and biologics approved since January 2011.

Novartis aims new Gilenya campaign at young MS patients

Novartis is thinking young. The Swiss drugmaker is using a cheeky ad campaign, targeted at 20- and 30-somethings not only in magazines, but via websites and social media. Novartis needs to find a new edge in the MS market, where it faces not only well-established injectable drugs, but two new oral rivals.

Biogen prices Tecfidera below oral MS rival Gilenya

Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.

Novartis MS drug could help beat bowel cancer

Novartis' multiple sclerosis drug Gilenya (fingolimod) could treat or even prevent colitis-associated cancer, if preclinical findings from U.S. researchers can be confirmed in later studies.

Eyeing Biogen drug, Teva demands review for new MS meds

Teva Pharmaceutical Industries ($TEVA) is very proud of its multiple sclerosis drug Copaxone. Thing is, Copaxone goes off patent in 2015.